Article: Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study

Objective: To compare the performance of three placental growth factor (PlGF)-based tests in predicting delivery within 14 days from testing in women with suspected preterm pre-eclampsia before 35 weeks' gestation.

Methods: This was a retrospective analysis of samples collected from three prospective pregnancy cohort studies. Participants were pregnant women with suspected preterm pre-eclampsia recruited in tertiary maternity units in the UK and Ireland. Samples were analyzed simultaneously according to the manufacturers' directions. The tests compared were the DELFIA Xpress PlGF 1-2-3 test, the Triage PlGF test and the Elecsys immunoassay soluble fms-like tyrosine kinase-1 (sFlt-1)/PlGF ratio. Areas under receiver-operating characteristics curves (AUCs) were compared. The main outcome measure was detection of a difference of 0.05 in AUC between tests for delivery within 14 days of testing.

Results: Plasma samples from 396 women and serum samples from 244 women were assayed. In predicting delivery within 14 days secondary to suspected pre-eclampsia prior to 35 weeks' gestation, no significant differences were observed in AUCs (P = 0.795), sensitivities (P = 0.249), positive predictive values (P = 0.765) or negative predictive values (P = 0.920) between the three tests. The specificity of the Elecsys sFlt-1/PlGF ratio test was higher than that of the other two tests (P < 0.001).

Conclusions: The tests perform similarly in their prediction of need for delivery within 14 days in women with suspected pre-eclampsia. The high negative predictive values support the role of PlGF-based tests as 'rule-out' tests for pre-eclampsia. © 2018 Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Citing Articles

Repeat Placental Growth Factor-Based Testing in Women With Suspected Preterm Preeclampsia: A Stratified Analysis of the PARROT-2 Trial.

Hurrell A, Webster L, Sparkes J, Battersby C, Brockbank A, Clark K Hypertension. 2024; 81(7):1561-1573.

PMID: 38708607 PMC: 11177603. DOI: 10.1161/HYPERTENSIONAHA.123.22411.

Placental Growth Factor (PlGF)- Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment.

Ont Health Technol Assess Ser. 2023; 23(3):1-146.

PMID: 37284279 PMC: 10241193.

Perspectives on the Use of Placental Growth Factor (PlGF) in the Prediction and Diagnosis of Pre-Eclampsia: Recent Insights and Future Steps.

Creswell L, OGorman N, Palmer K, da Silva Costa F, Rolnik D Int J Womens Health. 2023; 15:255-271.

PMID: 36816456 PMC: 9936876. DOI: 10.2147/IJWH.S368454.

Clinical tools and biomarkers to predict preeclampsia.

MacDonald T, Walker S, Hannan N, Tong S, Kaituu-Lino T EBioMedicine. 2021; 75:103780.

PMID: 34954654 PMC: 8718967. DOI: 10.1016/j.ebiom.2021.103780.

A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of....

Poon L, Magee L, Verlohren S, Shennan A, von Dadelszen P, Sheiner E Int J Gynaecol Obstet. 2021; 154 Suppl 1:3-31.

PMID: 34327714 PMC: 9290930. DOI: 10.1002/ijgo.13763.

References

1.

Robinson C, Johnson D, Chang E, Armstrong D, Wang W . Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol. 2006; 195(1):255-9. DOI: 10.1016/j.ajog.2005.12.049. View

2.

Cnossen J, Ter Riet G, Mol B, van der Post J, Leeflang M, Meads C . Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand. 2009; 88(7):758-65. DOI: 10.1080/00016340903008953. View

3.

Benton S, Hu Y, Xie F, Kupfer K, Lee S, Magee L . Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol. 2011; 205(5):469.e1-8. DOI: 10.1016/j.ajog.2011.06.058. View

4.

Chappell L, Duckworth S, Seed P, Griffin M, Myers J, Mackillop L . Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013; 128(19):2121-31. DOI: 10.1161/CIRCULATIONAHA.113.003215. View

5.

Griffin M, Seed P, Webster L, Myers J, Mackillop L, Simpson N . Diagnostic accuracy of placental growth factor and ultrasound parameters to predict the small-for-gestational-age infant in women presenting with reduced symphysis-fundus height. Ultrasound Obstet Gynecol. 2015; 46(2):182-90. PMC: 4744762. DOI: 10.1002/uog.14860. View

6.

Tranquilli A, Brown M, Zeeman G, Dekker G, Sibai B . The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens. 2015; 3(1):44-7. DOI: 10.1016/j.preghy.2012.11.001. View

7.

Zeisler H, Llurba E, Chantraine F, Vatish M, Staff A, Sennstrom M . Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016; 374(1):13-22. DOI: 10.1056/NEJMoa1414838. View

8.

Bramham K, Seed P, Lightstone L, Nelson-Piercy C, Gill C, Webster P . Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. Kidney Int. 2016; 89(4):874-85. DOI: 10.1016/j.kint.2015.10.012. View

9.

Stepan H, Hund M, Gencay M, Denk B, Dinkel C, Kaminski W . A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertens Pregnancy. 2016; 35(3):295-305. PMC: 5309866. DOI: 10.3109/10641955.2016.1141214. View

10.

Rolnik D, Wright D, Poon L, OGorman N, Syngelaki A, de Paco Matallana C . Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017; 377(7):613-622. DOI: 10.1056/NEJMoa1704559. View

Comparison of Three Commercially Available Placental Growth Factor-based Tests in Women with Suspected Preterm Pre-eclampsia: the COMPARE Study